On September 22, XTALPI rose 5.59% in regular trading, trading at HK$8.93/share, with turnover of HK$367 million. The stock has surged sharply in recent sessions, with a gain of over 16% in the prior trading day.

On the news front, the company announced that Board Chairman, Executive Director, and Co-founder Dr. Wen Shuhao plans to purchase shares on the open market using personal funds before the end of October, with a total consideration not exceeding HK$32 million. The Board stated the plan reflects Dr. Wen's confidence in the company's long-term development prospects and investment value. The company will not participate in or provide any financial assistance for the plan.

In addition, the company's wholly owned subsidiary LCC Technologies recently entered into a drug discovery collaboration agreement with Stanford University. The partnership combines Stanford's disease biology expertise with LCC Technologies' automated and AI-driven small-molecule drug discovery platform (PACE) to accelerate new drug development. A joint steering committee has been established to evaluate and advance promising research projects.

The company has also been actively conducting share buybacks throughout September, repurchasing and canceling shares on multiple occasions. These multiple positive catalysts have collectively boosted market sentiment toward the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)